Is DMT Legal in South Dakota? (2026)

Instrument

Hallucinogenic substances included in Schedule I

Source

https://sdlegislature.gov/api/Statutes/34-20B-14.html

Retrieved

2026-11-06

Fingerprint

d9c152c41a3fd42e

Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, is included in Schedule I, unless specifically excepted, whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
(59)    Substituted tryptamines. Any compound, unless specifically exempt, listed as a controlled substance in another schedule or an approved FDA drug, structurally derived from 2-(1H-indol-3-yl)ethanamine by mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom in a cyclic structure whether or not the compound is further substituted at the alpha-position with an alkyl group or whether or not further substituted on the indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups.
        Some trade and other names: 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin); 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DIPT); 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);

Instrument

Hallucinogenic substances included in Schedule I

Source

https://sdlegislature.gov/api/Statutes/34-20B-14.html

Retrieved

2026-10-31

Fingerprint

617956f45618b39a

Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, is included in Schedule I, unless specifically excepted, whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1)    Bufotenine;
(2)    Diethyltryptamine (DET);
(3)    Dimethyltryptamine (DMT);
(4)    5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT);
(5)    5-methoxy-3, 4-methylenedioxy amphetamine;
(6)    4-bromo-2, 5-dimethoxyamphetamine;
(7)    4-methoxyamphetamine;
(8)    4-methoxymethamphetamine;
(9)    4-methyl-2, 5-dimethoxyamphetamine;
(10)    Hashish and hash oil;
(11)    Ibogaine;
(12)    Lysergic acid diethylamide;
(13)    Mescaline;
(14)    N-ethyl-3-piperidyl benzilate;
(15)    N-methyl-3-piperidyl benzilate;
(16)    1-(-(2-thienyl)cyclohexyl) piperidine (TCP);
(17)    Peyote, except when used as a sacramental in services of the Native American church, in a natural state that is unaltered, except for drying or curing and cutting or slicing;
(18)    Psilocybin, except the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the United States Food and Drug Administration;
(19)    Psilocyn;

Instrument

Hallucinogenic substances included in Schedule I

Source

https://sdlegislature.gov/api/Statutes/34-20B-14.html

Retrieved

2026-11-06

Fingerprint

7fe638f515b87fbb

Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, is included in Schedule I, unless specifically excepted, whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1)    Bufotenine;
(2)    Diethyltryptamine (DET);
(3)    Dimethyltryptamine (DMT);
(4)    5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT);
(5)    5-methoxy-3, 4-methylenedioxy amphetamine;
(6)    4-bromo-2, 5-dimethoxyamphetamine;
(7)    4-methoxyamphetamine;
(8)    4-methoxymethamphetamine;
(9)    4-methyl-2, 5-dimethoxyamphetamine;
(10)    Hashish and hash oil;
(11)    Ibogaine;
(12)    Lysergic acid diethylamide;
(13)    Mescaline;
(14)    N-ethyl-3-piperidyl benzilate;
(15)    N-methyl-3-piperidyl benzilate;
(16)    1-(-(2-thienyl)cyclohexyl) piperidine (TCP);
(17)    Peyote, except when used as a sacramental in services of the Native American church, in a natural state that is unaltered, except for drying or curing and cutting or slicing;
(18)    Psilocybin, except the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the United States Food and Drug Administration;
(19)    Psilocyn;
(20)    Tetrahydrocannabinol, except that which occurs in industrial hemp as defined in § 
38-35-1
; in a drug product approved by the United States Food and Drug Administration; or marijuana in its natural and unaltered state; including any compound, except nabilone or compounds listed under a different schedule, structurally derived from 6,6Ν dimethyl-benzo[c]chromene by substitution at the 3-position with either alkyl (C3 to C8), methyl cycloalkyl, or adamantyl groups, whether or not the compound is further modified in any of the following ways:
(a)    By partial to complete saturation of the C-ring; or
(b)    By substitution at the 1-position with a hydroxyl or methoxy group; or
(c)    By substitution at the 9-position with a hydroxyl, methyl, or methylhydoxyl group; or
(d)    By modification of the possible 3-alkyl group with a 1,1Ν dimethyl moiety, a 1,1Ν cyclic moiety, an internal methylene group, an internal acetylene group, or a terminal halide, cyano, azido, or dimethylcarboxamido group.
        Some trade and other names: JWH-051; JWH-057; JWH-133; JWH-359; HHC; AM-087; AM-411; AM-855, AM-905; AM-906; AM-2389; HU-210; HU-211; HU-243; HU-336;
(21)    3, 4, 5-trimethoxy amphetamine;
(22)    3, 4-methylenedioxy amphetamine;
(23)    3-methoxyamphetamine;
(24)    2, 5-dimethoxyamphetamine;
(25)    2-methoxyamphetamine;
(26)    2-methoxymethamphetamine;
(27)    3-methoxymethamphetamine;
(28)    Phencyclidine;
(29)    3, 4-methylenedioxymethamphetamine (MDMA);
(30)    3, 4-methylenedioxy-N-ethylamphetamine;
(31)    N-hydroxy-3, 4-methylenedioxyamphetamine;
(32)    4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline);
(33)    2,5 Dimethoxy-4-ethylamphetamine;
(34)    N,N-Dimethylamphetamine;
(35)    1-(1-(2-thienyl)cyclohexyl)pyrrolidine;
(36)    Aminorex;
(37)    4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);
(38)    Cathinone and other variations, defined as any compound, material, mixture, preparation or other product unless listed in another schedule or an approved FDA drug, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways:
(a)    By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substitutents;
(b)    By substitution at the 3-position with an acyclic alkyl substituent; or
(c)    By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a cyclic structure.
        Some trade or other names: methcathinone, 4-methyl-N-methylcathinone (mephedrone); 3,4-methylenedioxy-N-methylcathinone (methylone); 3,4-methylenedioxypyrovalerone (MDPV); Naphthylpyrovalerone (naphyrone); 4-flouromethcathinone (flephedrone); 4-methoxymethcathinone (methedrone; Bk-PMMA); Ethcathinone (N-Ethylcathinone); 3,4-methylenedioxyethcathinone (ethylone); Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone); N,N-dimethylcathinone (metamfepramone); Alpha-pyrrolidinopropiophenone (alpha-PPP); 4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP); 3,4-methylenedioxyalphapyrrolidinopropiophenone (MDPPP); Alpha-pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone; 4Ν-Methyl-alpha-pyrrolidinobutiophenone (MPBP); Methyl-α-pyrrolindinopropiophenone (MPPP); Methyl-α-pyrrolidino-hexanophenone (MPHP); Buphedrone; Methyl-N-ethylcathinone; Pentedrone; Dimethylmethcathinone (DMMC); Dimethylethcathinone (DMEC); Methylenedioxymethcathinone (MDMC); Pentylone; Ethylethcathinone; Ethylmethcathinone; Fluoroethcathinone; methyl-alpha-pyrrolidinobutiophenone (MPBP); Methylecathinone (MEC); Methylenedioxy-alpha-pyrrolidinobutiophenone (MDPBP); Methoxymethcathinone (MOMC); Methylbuphedrone (MBP); Benzedrone (4-MBC); Dibutylone (DMBDB); Dimethylone (MDDMA); Diethylcathinone; Eutylone (EBDB); N-ethyl-N-Methylcathinone; N-ethylbuphedrone, 1-(1,3-benzodioxol-5-yl)2-(ethylamino)pentan-1-one (N-Ethylpentylone); 4'-Methyl-alpha-pyrrolidinopropiophenone (4-MEPPP, MPPP or MαPPP); alpha-Pyrrolidinobutiophenone (α-PBP); 1-(1,3-benzodioxol-5-yl)-2-(tert-butylamino)propan-1-one (Tertylone); 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)hexan-1-one (N-ethyl Hexylone); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pntan-1-one (Pentylone); N-ethylhexedrone (α ethylaminohexanophenone); alpha-pyrrolidinohexanophenone (α-PHP); 4-methyl-alpha-ethylaminopentiophenone (4-MEAP); 4′-methyl-alpha-pyrrolidinohexiophenone (MPHP); alpha-pyrrolidinoheptaphenone (PV8); 4′-chloro-alpha-pyrrolidinovalerophenone (4-chloro-α-PVP); Alpha-PIHP (4-methyl-1-phenyl-2-(pyrrolindin-1-yl)pentan-1-one;
(39)    2,5-Dimethoxy-4-ethylamphetamine (DOET);
(40)    Alpha-ethyltryptamine;
(41)    4-Bromo-2,5-dimethoxy phenethylamine;
(42)    2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);
(43)    1-(3-trifluoromethylphenyl) piperazine (TFMPP);
(44)    Alpha-methyltryptamine (AMT);
(45)    5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
(46)    5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);

Instrument

Hallucinogenic substances included in Schedule I - Substituted phenethylamine

Source

https://sdlegislature.gov/api/Statutes/34-20B-14.html

Retrieved

2026-07-20

Fingerprint

e39bd2b20306d405

Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, is included in Schedule I, unless specifically excepted, whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (58) Substituted phenethylamine. Any compound, unless specifically exempt, listed as a controlled substance in another schedule or an approved FDA drug, structurally derived from phenylethan-2-amine by substitution on the phenyl ring in any of the following ways: by substitution with a fused methylenedioxy, fused furan, or fused tetrahydrofuran ring system; by substitution with two alkoxy groups; by substitution with one alkoxy and either one fused furan, tetrahydrofuran, or tetrahydropyran ring system; by substitution with two fused ring systems from any combination of the furan, tetrahydrofuran, or tetrahydropyran ring systems; whether or not the compound is further modified in any of the following ways: (a) By substitution on the phenyl ring by any halo, hydroxyl, alkyl, trifluoromethyl, alkoxy, or alkylthio groups; (b) By substitution on the 2-position by any alkyl groups; or (c) By substitution on the 2-amino nitrogen atom with acetyl, alkyl, dialkyl, benzyl, methoxybenzyl, or hydroxybenzyl groups. Some trade and other names: 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine (2C-T or 4-methylthio-2,5-dimethoxyphenethylamine); 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine (DOI or 2, 5-Dimethoxy-4-iodoamphetamine); 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane (DOB or 2,5-Dimethoxy-4-bromoamphetamine); 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine (DOC or 2,5-Dimethoxy-4-chloroamphetamine); 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-B-NBOMe; 25B-NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine); 2-4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-I-NBOMe; 25I-NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine); N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxypheny (Mescaline-NBOMe or 3,4,5-trimethoxy-(2-methoxybenzyl)phenethylamine); 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-C-NBOMe; 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine); 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine (2CB-5-hemiFLY); 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-FLY); 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-yl)ethanamine (2C-B-butterFLY); -(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-bN]difuran-4-yl)-2-aminoethane (2C-B-FLY-NBOMe); 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (bromo-benzodifuranyl-isopropylamine or bromo-dragonFLY); -(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine (2C-I-NBOH or 25I-NBOH); 5-(2-Aminoprpyl)benzofuran (5-APB); 6(2-Aminopropyl)benzofuran (6-APB); 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB); 6-(2-Aminopropyl)-2,3,-dihydrobenzofuran (6-APDB); para-methoxymethamphetamine (PMMA);

Instrument

Schedule I substituted tryptamines

Source

https://sdlegislature.gov/api/Statutes/34-20B-14.html

Retrieved

2026-10-29

Fingerprint

3c09c431c95d6bb7

(59)    Substituted tryptamines. Any compound, unless specifically exempt, listed as a controlled substance in another schedule or an approved FDA drug, structurally derived from 2-(1H-indol-3-yl)ethanamine by mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom in a cyclic structure whether or not the compound is further substituted at the alpha-position with an alkyl group or whether or not further substituted on the indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups.
        Some trade and other names: 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin); 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DIPT); 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);

Instrument

Specific substances included in Schedule III

Source

https://sdlegislature.gov/api/Statutes/34-20B-22.html

Retrieved

2026-10-31

Fingerprint

a6e3dda9d6f988af

The following are included in Schedule III:
(1)    Nalorphine;
(2)    Preparations which contain both Tiletamine and Zolazepam;
(3)    Anabolic steroids as listed in § 
34-20B-4.1
;
(4)    Ketamine.